Literature DB >> 2193504

Autoimmune cytopenias in Castleman's disease.

P A Carrington1, H Anderson, M Harris, S E Walsh, J B Houghton, G R Morgenstern.   

Abstract

The authors report a case of Castleman's disease in which the major clinical problems have been caused by severe thrombocytopenia and neutropenia. The cytopenias were caused by autoimmune destruction of mature cells as demonstrated by bone marrow findings and cell-specific antibody assays. There also was evidence of red cell autoantibody production but no overt hemolysis. The thrombocytopenia currently is controlled by intermittent vincristine, having proved refractory to steroids, splenectomy, and danazol and only partially responsive to high dose intravenous immunoglobulin. The neutropenia showed temporary improvement with immunoglobulin but has been resistant to all other therapy. This case provides further evidence for disordered immune regulation in Castleman's disease.

Entities:  

Mesh:

Year:  1990        PMID: 2193504     DOI: 10.1093/ajcp/94.1.101

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 2.  Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians.

Authors:  Piero Farruggia; Carlo Dufour
Journal:  Ther Adv Hematol       Date:  2015-02

3.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

Review 4.  An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis.

Authors:  Yuriko Morita-Hoshi; Shuji Tohda; Osamu Miura; Nobuo Nara
Journal:  Int J Hematol       Date:  2007-12-08       Impact factor: 2.490

Review 5.  Immune neutropenias of infancy and childhood.

Authors:  Piero Farruggia
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

Review 6.  Multicentric Castleman's disease in two cases.

Authors:  Rajni Sharma; Rachna Seth; V Thavaraj; A Bagga; S K Kabra; A K Karak; S Atri
Journal:  Indian J Pediatr       Date:  2007-12       Impact factor: 5.319

Review 7.  Updates on the diagnosis and management of multicentric Castleman disease.

Authors:  Ya-Ju Wu; Kuei-Ying Su
Journal:  Tzu Chi Med J       Date:  2020-07-29

8.  Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.

Authors:  Akira Tomonari; Naoki Shirafuji; Arinobu Tojo; Tohru Iseki; Jun Ooi; Itaru Komiya; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.319

9.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.